QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS5-Region Domestic Shipping
What is Tirzepatide?
Tirzepatide (Dual GIP+GLP-1 receptor agonist) is a 39-amino acid dual-modified synthetic peptide. First approved dual GIP and GLP-1 receptor co-agonist — one molecule activating both incretin receptors simultaneously. GIPR co-agonism adds: adipose lipolysis, thermogenesis, and hypothalamic GLP-1R sensitisation. SURMOUNT-5 (2025): 20.2% vs 13.7% mean weight reduction vs semaglutide 2.4mg at 72 weeks. SURPASS-2: superior HbA1c vs semaglutide 1mg.
Research Applications
Dual Incretin Pharmacology
GIP+GLP-1R co-agonism, receptor interaction, GIPR adipose signalling
T2D Research
SURPASS program — up to 2.58% HbA1c reduction vs placebo
Obesity Models
SURMOUNT-1: 22.5% weight reduction (15mg, 72 weeks)
NASH/Liver
SYNERGY-NASH: 62.4% NASH resolution at 10mg
vs Semaglutide
Head-to-head SURMOUNT-5 reference compound
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | 2023788-19-2 |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Peptide Type | Dual GIP/GLP-1 Receptor Agonist |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | -20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | 24 months unopened |




